CARD8 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease

Adeline Germain1, Rosa-Maria Guéant2, Mathias Chamaillard3

  • 1Department of Digestive Surgery, University Hospital of Nancy-Brabois, Vandoeuvre-les-Nancy, France; INSERM U954, Nutrition-Génétique et Exposition aux risques environnementaux, Faculté de Médecine, Université de Lorraine, Vandoeuvre-les-Nancy, France.

Insights

Identifying genetic factors for Crohn's disease recurrence is crucial. Caspase recruitment domain-containing protein 8 (CARD8) homozygosity is a novel predictor of repeat surgery, alongside smoking and prior complications.

Area of Science:

  • Gastroenterology
  • Genetics
  • Surgical Outcomes

Background:

  • Post-operative recurrence is a significant challenge in Crohn's disease management.
  • Genetic factors influencing surgical recurrence are not well understood.
  • Risk stratification is needed for targeted therapies to prevent repeat surgeries.

Purpose of the Study:

  • To identify genetic variants associated with post-operative surgical recurrence in Crohn's disease.
  • To evaluate the role of genetic factors in predicting the need for repeat surgeries.
  • To explore potential new markers for risk stratification.

Main Methods:

  • Retrospective analysis of Crohn's disease patients with at least one bowel resection from the "Nancy IBD cohort".
  • Cox proportional hazard model used for covariate and interaction assessment.
  • Kaplan-Meier curves and log-rank tests applied to analyze 200 genetic variants for time to surgical recurrence.

Main Results:

  • 28% of 137 patients experienced surgical recurrence.
  • Current smoking status, prior post-operative complications, and Caspase recruitment domain-containing protein 8 (CARD8) homozygosity for the risk allele were independently associated with recurrence.
  • CARD8 homozygosity showed a significant association (OR 7.56, p=0.036).

Conclusions:

  • Current smoking is a significant risk factor for surgical recurrence in Crohn's disease.
  • A novel association between CARD8 gene variants and increased risk of surgical recurrence was identified.
  • CARD8 may serve as a valuable marker for stratifying patient risk and preventing recurrent surgeries.
Abstract

Related Concept Videos

Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
854
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
686
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
653
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
764